Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

ATIR101
Read More
ATIR101 is an immunotherapeutic delivered as an adjunctive therapy for patients receiving HSCT.
July 6, 2017
Find out more
Orenitram
Read More
United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.
October 19, 2018
Find out more
Firsocostat
Read More
Firsocostat (Gilead) is an acetyl-CoA carboxylase (ACC) allosteric inhibitor which binds to the biotin carboxylase domain of ACC with high potency and selectivity. Firsocostat inhibits both isoforms (ACC1 and ACC2) of ACC, which results in the reduction of the production of malonyl-CoA carboxylase, therefore reducing a key substrate for fatty acid synthesis. This also reduces the inhibitory effect of malonyl-CoA on the carnitine palmitoyltransferase 1 (CPT-1), which is the rate-limiting step in β-oxidation and leads to an increase in the breakdown of free fatty acids.
July 22, 2019
Find out more
Tivicay
Read More
Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Ibrance
Read More
Ibrance (palbociclib; Pfizer) is a small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). When associated with cyclin-D proteins, CDK4/6 are able to phosphorylate and inactivate.
February 4, 2016
Find out more
DCVax-L
Read More
DCVax-L (Northwest Biotherapeutics) is a dendritic cell vaccine in development for the treatment of glioblastoma multiforme (GBM). It is a personalized immunotherapy that utilizes patients’ own dendritic cells to stimulate…
April 13, 2016
Find out more
Entrectinib
Read More
Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
August 30, 2018
Find out more
BeneFix
Read More
BeneFIX (Pfizer) is an recombinant factor IX (rfIX) therapy indicated for the control and prevention of bleeding in hemophilia B.
May 4, 2018
Find out more
Veliparib
Read More
Veliparib is a small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AbbVie. PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events.
February 26, 2020
Find out more
Yonsa
Read More
Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.
January 18, 2018
Find out more
Imbruvica
Read More
Imbruvica is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
January 31, 2019
Find out more
Ublituximab
Read More
Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.
January 31, 2019
Find out more
Lipitor
Read More
Pfizer’s Lipitor (atorvastatin calcium) acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase.
June 22, 2018
Find out more
Geodon
Read More
Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer.
April 9, 2018
Find out more
Votrient
Read More
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis
March 6, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *